135 related articles for article (PubMed ID: 21120063)
1. Parkinson's disease: general features, effects of levodopa treatment and future directions.
Freire MA; Santos JR
Front Neuroanat; 2010 Nov; 4():146. PubMed ID: 21120063
[No Abstract] [Full Text] [Related]
2. Changing epidemiology of Parkinson's disease: predicted effects of levodopa treatment.
Marttila RJ; Rinne UK
Acta Neurol Scand; 1979 Mar; 59(2-3):80-7. PubMed ID: 452843
[TBL] [Abstract][Full Text] [Related]
3. Effects of levodopa on corticostriatal circuits supporting working memory in Parkinson's disease.
Simioni AC; Dagher A; Fellows LK
Cortex; 2017 Aug; 93():193-205. PubMed ID: 28675834
[TBL] [Abstract][Full Text] [Related]
4. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry.
Ben-Shlomo Y; Churchyard A; Head J; Hurwitz B; Overstall P; Ockelford J; Lees AJ
BMJ; 1998 Apr; 316(7139):1191-6. PubMed ID: 9583926
[TBL] [Abstract][Full Text] [Related]
5. Ropinirole: a review of its use in the management of Parkinson's disease.
Matheson AJ; Spencer CM
Drugs; 2000 Jul; 60(1):115-37. PubMed ID: 10929932
[TBL] [Abstract][Full Text] [Related]
6. Rhythm-specific modulation of the sensorimotor network in drug-naive patients with Parkinson's disease by levodopa.
Esposito F; Tessitore A; Giordano A; De Micco R; Paccone A; Conforti R; Pignataro G; Annunziato L; Tedeschi G
Brain; 2013 Mar; 136(Pt 3):710-25. PubMed ID: 23423673
[TBL] [Abstract][Full Text] [Related]
7. Effects of deep brain stimulation and levodopa on postural sway in Parkinson's disease.
Rocchi L; Chiari L; Horak FB
J Neurol Neurosurg Psychiatry; 2002 Sep; 73(3):267-74. PubMed ID: 12185157
[TBL] [Abstract][Full Text] [Related]
8. [Perioperative management of a patient with Parkinson's disease with intravenous infusion of levodopa].
Mizuno J; Kato S; Watada M; Morita S
Masui; 2009 Oct; 58(10):1286-9. PubMed ID: 19860235
[TBL] [Abstract][Full Text] [Related]
9. Natural history of motor symptoms in Parkinson's disease and the long-duration response to levodopa.
Cilia R; Cereda E; Akpalu A; Sarfo FS; Cham M; Laryea R; Obese V; Oppon K; Del Sorbo F; Bonvegna S; Zecchinelli AL; Pezzoli G
Brain; 2020 Aug; 143(8):2490-2501. PubMed ID: 32844196
[TBL] [Abstract][Full Text] [Related]
10. Abnormal bidirectional plasticity-like effects in Parkinson's disease.
Huang YZ; Rothwell JC; Lu CS; Chuang WL; Chen RS
Brain; 2011 Aug; 134(Pt 8):2312-20. PubMed ID: 21742734
[TBL] [Abstract][Full Text] [Related]
11. Effects of Parkinson's disease and levodopa on functional limits of stability.
Mancini M; Rocchi L; Horak FB; Chiari L
Clin Biomech (Bristol, Avon); 2008 May; 23(4):450-8. PubMed ID: 18155331
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and safety/efficacy of levodopa pro-drug ONO-2160/carbidopa for Parkinson's disease.
Nomoto M; Nagai M; Nishikawa N; Ando R; Kagamiishi Y; Yano K; Saito S; Takeda A
eNeurologicalSci; 2018 Dec; 13():8-13. PubMed ID: 30294682
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Parkinson's disease: problems with a progressing disease.
Rinne UK
J Neural Transm; 1981; 51(1-2):161-74. PubMed ID: 7264627
[TBL] [Abstract][Full Text] [Related]
14. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Clarke CE; Deane KH
Cochrane Database Syst Rev; 2001; (1):CD001517. PubMed ID: 11279719
[TBL] [Abstract][Full Text] [Related]
15. Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.
Najib J
Clin Ther; 2001 Jun; 23(6):802-32; discussion 771. PubMed ID: 11440283
[TBL] [Abstract][Full Text] [Related]
16. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom.
BMJ; 1993 Aug; 307(6902):469-72. PubMed ID: 8400928
[TBL] [Abstract][Full Text] [Related]
17. Does Late Levodopa Administration Delay the Development of Dyskinesia in Patients with De Novo Parkinson's Disease?
Chung SJ; Yoo HS; Lee HS; Jeong HE; Kim SJ; Oh JS; Kim JS; Sohn YH; Lee PH
CNS Drugs; 2018 Oct; 32(10):971-979. PubMed ID: 30027399
[TBL] [Abstract][Full Text] [Related]
18. The Effect of Levodopa on Improvements in Protective Stepping in People With Parkinson's Disease.
Peterson DS; Horak FB
Neurorehabil Neural Repair; 2016 Nov; 30(10):931-940. PubMed ID: 27162165
[TBL] [Abstract][Full Text] [Related]
19. Ongoing challenges to finding people with Parkinson's disease for epidemiological studies: a comparison of population-level case ascertainment methods.
Harris MA; Koehoorn M; Teschke K
Parkinsonism Relat Disord; 2011 Jul; 17(6):464-9. PubMed ID: 21531606
[TBL] [Abstract][Full Text] [Related]
20. Force overflow and levodopa-induced dyskinesias in Parkinson's disease.
Wenzelburger R; Zhang BR; Pohle S; Klebe S; Lorenz D; Herzog J; Wilms H; Deuschl G; Krack P
Brain; 2002 Apr; 125(Pt 4):871-9. PubMed ID: 11912119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
